Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10910893 | Lung Cancer | 2015 | 7 Pages |
Abstract
Our findings suggested that only patients with rare EGFR mutations could receive platinum-based chemotherapy as a first-line treatment, due to their low response rates and short PFS in response to EGFR-TKIs. Consequently, EGFR-TKIs could be reserved as a second- or third-line treatment. In patients with EGFR mutations, women have better PFS to EGFR-TKIs than men, and rare EGFR mutations are more frequent in high grade adenocarcinomas than in low grade tumors.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Oscar Arrieta, Andrés Felipe Cardona, Luis Corrales, Alma Delia Campos-Parra, Roberto Sánchez-Reyes, Eduardo Amieva-Rivera, July RodrÃguez, Carlos Vargas, Hernán Carranza, Jorge Otero, Nikki Karachaliou, Horacio Astudillo, Rafael Rosell,